Clinical Trial Update: An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

View source ↗

Summary

This completed observational real-world study describes and compares the use and effectiveness of darolutamide, enzalutamide, and apalutamide in men with non-me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Nubeqa (darolutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Bayer | Conditions: Non-metastatic Castration-resistant Prostate Cancer | Status: COMPLETED